BACKGROUND: Children are highly vulnerable to infection with novel influenza viruses. It is essential to develop candidate pandemic influenza vaccines that are safe and effective in the pediatric population. METHODS:Infants and children aged 6-35 months and 3-8 years, respectively, were randomized to receive 2 immunizations with a 7.5-µg or 3.75-µg hemagglutinin (HA) dose of a nonadjuvanted whole-virus A/Vietnam(H5N1) vaccine; adolescents aged 9-17 years received a 7.5-µg dose only. A subset of participants received a booster immunization with an A/Indonesia(H5N1) vaccine approximately 1 year later. HA and neuraminidase antibody responses were assessed. RESULTS: Vaccination was safe and well tolerated; adverse reactions were transient and predominantly mild. Two immunizations with the 7.5-µg dose of A/Vietnam vaccine induced virus microneutralization (MN) titers of ≥1:20 against the A/Vietnam strain in 68.8%-85.4% of participants in the different age groups. After the booster, 93.1%-100% of participants achieved MN titers of ≥1:20 against the A/Vietnam and A/Indonesia strains. Neuraminidase-inhibiting antibodies were induced in ≥90% of participants after 2 immunizations with the 7.5 µg A/Vietnam vaccine and in 100% of participants after the booster. CONCLUSIONS: A whole-virus influenza A(H5N1) vaccine is suitable for prepandemic or pandemic immunization in a pediatric population. CLINICAL TRIALS REGISTRATION: NCT01052402.
RCT Entities:
BACKGROUND:Children are highly vulnerable to infection with novel influenza viruses. It is essential to develop candidate pandemic influenza vaccines that are safe and effective in the pediatric population. METHODS:Infants and children aged 6-35 months and 3-8 years, respectively, were randomized to receive 2 immunizations with a 7.5-µg or 3.75-µg hemagglutinin (HA) dose of a nonadjuvanted whole-virus A/Vietnam(H5N1) vaccine; adolescents aged 9-17 years received a 7.5-µg dose only. A subset of participants received a booster immunization with an A/Indonesia(H5N1) vaccine approximately 1 year later. HA and neuraminidase antibody responses were assessed. RESULTS: Vaccination was safe and well tolerated; adverse reactions were transient and predominantly mild. Two immunizations with the 7.5-µg dose of A/Vietnam vaccine induced virus microneutralization (MN) titers of ≥1:20 against the A/Vietnam strain in 68.8%-85.4% of participants in the different age groups. After the booster, 93.1%-100% of participants achieved MN titers of ≥1:20 against the A/Vietnam and A/Indonesia strains. Neuraminidase-inhibiting antibodies were induced in ≥90% of participants after 2 immunizations with the 7.5 µg A/Vietnam vaccine and in 100% of participants after the booster. CONCLUSIONS: A whole-virus influenza A(H5N1) vaccine is suitable for prepandemic or pandemic immunization in a pediatric population. CLINICAL TRIALS REGISTRATION: NCT01052402.
Authors: Maikel V W van der Velden; Alexander Geisberger; Thomas Dvorak; Daniel Portsmouth; Richard Fritz; Brian A Crowe; Wolfgang Herr; Eva Distler; Eva M Wagner; Markus Zeitlinger; Robert Sauermann; Christoph Stephan; Hartmut J Ehrlich; P Noel Barrett; Gerald Aichinger Journal: Clin Vaccine Immunol Date: 2014-04-16
Authors: Gerald Aichinger; Barbara Grohmann-Izay; Maikel V W van der Velden; Sandor Fritsch; Manuela Koska; Daniel Portsmouth; Mary Kate Hart; Wael El-Amin; Otfried Kistner; P Noel Barrett Journal: Clin Vaccine Immunol Date: 2014-10-29
Authors: Richard Fritz; Nicole Hetzelt; Reinhard Ilk; Christine Hohenadl; Maikel V W van der Velden; Gerald Aichinger; Daniel Portsmouth; Otfried Kistner; M Keith Howard; P Noel Barrett; Thomas R Kreil Journal: Open Forum Infect Dis Date: 2014-08-25 Impact factor: 3.835
Authors: Walter Wodal; Michael G Schwendinger; Helga Savidis-Dacho; Brian A Crowe; Christine Hohenadl; Richard Fritz; Peter Brühl; Daniel Portsmouth; Anita Karner-Pichl; Dalida Balta; Leopold Grillberger; Otfried Kistner; P Noel Barrett; M Keith Howard Journal: PLoS One Date: 2015-02-26 Impact factor: 3.240